Skip to main content
SpringerLink
Log in
Book cover

Knochenmetastasen pp 193–203Cite as

Ossäre Manifestationen des multiplen Myeloms

  • Chapter
  • First Online:

  • 1883 Accesses

Zusammenfassung

Das multiple Myelom ist eine Erkrankung von terminal differenzierten B-Lymphozyten, den Myelomzellen. Die Knochendestruktion steht bei den Myelompatienten im Mittelpunkt der Krankheitsaktivität. Die moderne Bildgebung lässt diese Knochenveränderungen bereits früh erkennen. Insbesondere in der MRT sind Knochenmarkveränderungen im Sinne von Läsionen darstellbar. Aufgrund der höheren Sensitivität der Bildgebungsverfahren können durch einen früheren Beginn einer systemischen oder lokalen Therapie Knochenkomplikationen vermieden oder reduziert werden. Neue Substanzen werden beim multiplen Myelom hinsichtlich der Prävention von skelettassoziierten Events prospektiv geprüft, und sie werden das Repertoire der Behandlung der Knochenerkrankung beim multiplen Myelom erweitern Die Reduktion von Knochendestruktionen bei Patienten mit multiplem Myelom verbessert die Lebensqualität. Die Bisphosphonattherapie mit Zoledronsäure führt zu einer PFS- und OS-Verlängerung.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Abe M, Hiura K, Wilde J et al (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104(8): 2484–2491

    Article  CAS  PubMed  Google Scholar 

  • Andersen TL, Sondergaard TE, Skorzynska KE et al (2009) A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 174(1): 239–247

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Avet-Loiseau H, Attal M, Moreau P et al (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109(8): 3489–3495

    Article  CAS  PubMed  Google Scholar 

  • Barlogie B, Tricot G, Rasmussen E et al (2006) Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107(7): 2633–2638

    Article  CAS  PubMed  Google Scholar 

  • Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990 Fortschreibung im Internet: www.krebsatlas.de: Springer, Berlin Heidelberg New York

  • Caers J, Hose D, Kuipers I et al (2010) Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica 95(1): 163–167

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Djulbegovic B, Wheatley K, Ross J et al (2002) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002(3): CD003188

    Google Scholar 

  • Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6): 1374–1403

    Article  CAS  PubMed  Google Scholar 

  • Goldschmidt H, Cremer FW (2002) Klinische Manifestation. Das Multiple Myelom (Plasmozytom) Diagnose und Therapie. UNI-MED, Bremen, S 29–33

    Google Scholar 

  • Hageman K, Patel KC, Mace K, Cooper MR (2013) The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 47(7–8): 1069–1074

    Article  PubMed  Google Scholar 

  • Hillengass J, Fechtner K, Weber M-A et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28(9): 1606–1610

    Article  PubMed  Google Scholar 

  • Hillengass J, Ayyaz S, Kilk K et al (2012) Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 97(11): 1757–1760

    Article  PubMed Central  PubMed  Google Scholar 

  • Hose D, Rème T, Meissner T et al (2009a) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18): 4331–4340

    Article  CAS  Google Scholar 

  • Hose D, Moreaux J, Meissner T et al (2009b) Induction of angiogenesis by normal and malignant plasma cells. Blood 114(1): 128–143

    Article  CAS  Google Scholar 

  • Hose D, Reme T, Hielscher T et al (2011) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96: 87–95

    Article  PubMed Central  PubMed  Google Scholar 

  • Kasperk C, Haas A, Hillengass J et al (2012) Kyphoplasty in patients with multiple myeloma a retrospective comparative pilot study. J Surg Oncol 105(7): 679–686

    Article  PubMed  Google Scholar 

  • Klein B, Seckinger A, Moehler T, Hose D (2011) Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res 183: 39–86

    Article  PubMed  Google Scholar 

  • Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18): 1860–1873

    Article  CAS  PubMed  Google Scholar 

  • Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, Mayo Clinic 78(1): 21–33

    Article  Google Scholar 

  • Kyle RA, Remstein ED, Therneau TM et al (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25): 2582–2590

    Article  CAS  PubMed  Google Scholar 

  • Kyle RA, Durie BGM, Rajkumar SV et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24(6): 1121–1127

    Article  CAS  PubMed  Google Scholar 

  • Mahtouk K, Hose D, Rème T et al (2005) Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24(21): 3512–3524

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mahtouk K, Hose D, Raynaud P et al (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109(11): 4914–4923

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Melton LJ, Kyle RA, Achenbach SJ et al (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Mineral Res 20(3): 487–493

    Article  Google Scholar 

  • Moreaux J, Legouffe E, Jourdan E et al (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8): 3148–3157

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Moreaux J, Cremer FW, Reme T et al (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106(3): 1021–1030

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Moreaux J, Hose D, Kassambara A et al (2011) Osteoclast-gene expression profiling reveals osteoclast-derived CCR2-chemokines promoting myeloma cell migration. Blood 117: 1280–1290

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Morgan GJ, Davies FE, Gregory WM et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376: 1989–1999

    Article  CAS  PubMed  Google Scholar 

  • Mori Y, Shimizu N, Dallas M et al (2004) Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104(7): 2149–2154

    Article  CAS  PubMed  Google Scholar 

  • Neben K, Jauch A, Bertsch U et al (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95(7): 1150–1157

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Neben K, Lokhorst HM, Jauch A et al (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119(4): 940–948

    Article  CAS  PubMed  Google Scholar 

  • Neben K, Jauch A, Hielscher T et al (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31(34): 4325–4332

    Article  PubMed  Google Scholar 

  • Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8): 1860–1867

    Article  PubMed  Google Scholar 

  • Seckinger A, Meissner T, Moreaux J et al (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28(44): 3866–3879

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Seckinger A, Meißner T, Moreaux J et al (2012) Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120(5): 1087–1094

    Article  CAS  PubMed  Google Scholar 

  • Seckinger A, Meißner T, Bertsch U et al (2013) Bone turnover in multiple myeloma: impact of bortezomib-based induction therapy, high-dose melphalan, and lenalidomide consolidation on osteoblast and osteoclast function within the GMMG-MM5 Trial. ASH Annual Meeting, Abstract 1863

    Google Scholar 

  • Shain KH, Yarde DN, Meads MB et al (2009) β1 Integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69(3): 1009–1015

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sprynski AC, Hose D, Caillot L et al (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113(19): 4614–4626

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tai Y-T, Podar K, Catley L et al (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3’-kinase/AKT signaling. Cancer Res 63(18): 5850–5858

    CAS  PubMed  Google Scholar 

  • Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20(8): 1303–1317

    Article  CAS  PubMed  Google Scholar 

  • Terpos E, Morgan G, Dimopoulos MA et al (2013) International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 31(18): 2347–2357

    Article  CAS  PubMed  Google Scholar 

  • Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26): 2483–2494

    Article  CAS  PubMed  Google Scholar 

  • Walker R, Barlogie B, Haessler J et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25(9): 1121–1128

    Article  PubMed  Google Scholar 

  • Weinhold N, Johnson DC, Chubb D et al (2013) The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 45(5): 522–525

    Article  CAS  PubMed  Google Scholar 

  • Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118(23): 5989–5995

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V, Universitätsklinikum Heidelberg und Nationales Centrum für Tumorerkrankungen (NTC), Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    Hartmut Goldschmidt

  2. Medizinische Klinik V (Hämatologie – Onkologie – Rheumatologie), Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    Dirk Hose

  3. Medizinische Klinik V (Hämatologie – Onkologie – Rheumatologie), Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland

    Jens Hillengaß

Authors
  1. Hartmut Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Hose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jens Hillengaß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hartmut Goldschmidt .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Arnulf Stenzl

  2. Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany

    Tanja Fehm

  3. Medizinische Klinik III, Bereich Endokrinologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany

    Lorenz C. Hofbauer

  4. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Würzburg, Germany

    Franz Jakob

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Goldschmidt, H., Hose, D., Hillengaß, J. (2014). Ossäre Manifestationen des multiplen Myeloms. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43471-0_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43470-3

  • Online ISBN: 978-3-662-43471-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation